Achieve Life Sciences (ACHV) Free Cash Flow (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Free Cash Flow of -$6.9 million in Q1 2026, up 61.49% on a QoQ basis from -$18.0 million in Q4 2025, and up 37.48% year-over-year from -$5.0 million in Q1 2025.
Achieve Life Sciences (ACHV) Free Cash Flow (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Free Cash Flow across 17 years of filings, most recently posting -$6.9 million for Q1 2026.
- Quarterly Free Cash Flow rose 37.48% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.3 million (down 27.48% YoY) and the FY2025 annual result came in at -$49.5 million, down 66.28% from the prior year.
- Free Cash Flow rose to -$6.9 million in Q1 2026, from -$18.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$4.4 million in Q4 2023 and troughed at -$18.0 million in Q4 2025.
- A 5-year average of -$8.7 million and a median of -$8.3 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 113.55% — and 2023, when it soared 60.78%.
- Tracing ACHV's Free Cash Flow over 5 years: stood at -$11.1 million in 2022, then surged by 60.78% to -$4.4 million in 2023, then sank by 110.27% to -$9.2 million in 2024, then tumbled by 95.89% to -$18.0 million in 2025, then soared by 61.49% to -$6.9 million in 2026.
- Business Quant data shows ACHV's Free Cash Flow at -$6.9 million in Q1 2026, -$18.0 million in Q4 2025, and -$11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 63,220.27 |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | -6.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.93 Mn |
| Mar 31, 2026 | -6.93 Mn |
| Dec 31, 2025 | -18.00 Mn |
| Dec 31, 2025 | -18.00 Mn |
| Sep 30, 2025 | -11.34 Mn |
| Sep 30, 2025 | -11.34 Mn |
| Jun 30, 2025 | -9.07 Mn |
| Jun 30, 2025 | -9.07 Mn |
| Mar 31, 2025 | -11.09 Mn |
| Mar 31, 2025 | -11.09 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Dec 31, 2024 | -9.19 Mn |
| Sep 30, 2024 | -10.37 Mn |
| Sep 30, 2024 | -10.37 Mn |
| Jun 30, 2024 | -4.92 Mn |
| Jun 30, 2024 | -4.92 Mn |
| Mar 31, 2024 | -5.29 Mn |
| Mar 31, 2024 | -5.29 Mn |
| Dec 31, 2023 | -4.37 Mn |
| Dec 31, 2023 | -4.37 Mn |